Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 35Recurrence 27Multiple Myeloma 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 25Lymphoma 20Neoplasms 16Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 15Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Mantle-Cell 13Leukemia 13Carcinoma, Non-Small-Cell Lung 13Stomach Neoplasms 11Ovarian Neoplasms 9Pancreatic Neoplasms 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Myelodysplastic Syndromes 6Melanoma 6Lymphoma, B-Cell, Marginal Zone 6Breast Neoplasms 6Prostatic Neoplasms 5Liposarcoma, Myxoid 5Colorectal Neoplasms 5

Interventions

Data Collection 3fludarabine 2Cyclophosphamide 2telitacicept 1human papillomavirus vaccine, L1 type 16, 18 1Watchful Waiting 1Plasma Exchange 1Phlebotomy 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Autoimmune Diseases × fludarabine × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Arcellx, Inc.

Phase 1 Recruiting
30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡